Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18293Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Karagiannis, A. | en |
| dc.contributor.author | Athyros, V. G. | en |
| dc.contributor.author | Papageorgiou, A. | en |
| dc.contributor.author | Tziomalos, K. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T18:51:41Z | - |
| dc.date.available | 2015-11-24T18:51:41Z | - |
| dc.identifier.issn | 1109-9666 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18293 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adrenergic beta-Antagonists/*therapeutic use | en |
| dc.subject | Atenolol/*therapeutic use | en |
| dc.subject | Blood Pressure/drug effects | en |
| dc.subject | Humans | en |
| dc.subject | Hypertension/*drug therapy/mortality/physiopathology | en |
| dc.subject | Randomized Controlled Trials as Topic | en |
| dc.subject | Survival Rate | en |
| dc.title | Should atenolol still be recommended as first-line therapy for primary hypertension? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17134065 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.journalName | Hellenic J Cardiol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Elisaf-2006-should atenolol still.pdf | 348.23 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
